The recent publication of several large randomized controlled trials (RCTs) reported the benefits of SGLT2 inhibitors on the decrease in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) levels in T1DM with insulin therapy [19–34]. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.